BioPharma Resources

Drug Trial Radar · NCT07624305

A Phase III Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With CKD Stage 3b and 4 (BalanceD-CKD)

A Phase III, Randomised, Double-blind, Study to Evaluate the Effect of Balcinrenone/Dapagliflozin Compared With Dapagliflozin on Renal and Cardiovascular Outcomes in Patients With Chronic Kidney Disease (Stage 3b and 4)

Last checked: Nov 19, 2026Latest source record: Sep 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 2,800 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

2,800

Planned (sponsor's estimate)

Start

Sep 1, 2026

Primary completion

Jul 1, 2030

Study completion Jul 1, 2030

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Jun 3, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 99 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy, safety and tolerability of balcinrenone in fixed combination with dapagliflozin, compared with dapagliflozin, in patients with CKD Stage 3b and 4 (eGFR ≥ 15 to \< 45 mL/min/1.73 m2) administered orally once daily in addition to SoC. This is a population with high unmet medical need and an increased risk of CKD progression, who are frequently excluded from interventional trials.

Conditions

  • Renal Insufficiency, Chronic

Interventions

  • Balcinrenone/dapagliflozinDrug

    balcinrenone/dapagliflozin 15 mg/10 mg

  • DapagliflozinDrug

    dapagliflozin 10 mg

  • Placebo matching DapagliflozinDrug

    matching placebo for dapagliflozin 10 mg

  • Placebo matching balcinrenone/dapagliflozinDrug

    matching placebo for balcinrenone/dapagliflozin

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to first occurrence of cardiovascular death, death from kidney failure, kidney failure, sustained 50% or greater decline in eGFR, and heart failure eventTime frame: Up to 46 months.

Locations

478 sites in 27 countries. Site status is shown where the registry gives one.

  • Research Site

    Huntsville, Alabama · Not yet recruiting

  • Research Site

    Surprise, Arizona · Recruiting

  • Research Site

    Tempe, Arizona · Not yet recruiting

  • Research Site

    Little Rock, Arkansas · Not yet recruiting

  • Research Site

    Concord, California · Recruiting

  • Research Site

    Daly City, California · Not yet recruiting

  • Research Site

    Fremont, California · Not yet recruiting

  • Research Site

    Huntington Park, California · Not yet recruiting

  • Research Site

    Lancaster, California · Not yet recruiting

  • Research Site

    Lynwood, California · Not yet recruiting

  • Research Site

    Northridge, California · Not yet recruiting

  • Research Site

    Palo Alto, California · Not yet recruiting

  • Research Site

    Pomona, California · Not yet recruiting

  • Research Site

    Riverside, California · Not yet recruiting

  • Research Site

    San Dimas, California · Not yet recruiting

  • Research Site

    Tarzana, California · Not yet recruiting

  • Research Site

    Washington D.C., District of Columbia · Not yet recruiting

  • Research Site

    Boca Raton, Florida · Not yet recruiting

  • Research Site

    Fort Lauderdale, Florida · Not yet recruiting

  • Research Site

    Gainesville, Florida · Not yet recruiting

  • Research Site

    Hollywood, Florida · Not yet recruiting

  • Research Site

    Jacksonville Beach, Florida · Not yet recruiting

  • Research Site

    Lakeland, Florida · Not yet recruiting

  • Research Site

    Melbourne, Florida · Suspended

  • Research Site

    Orlando, Florida · Not yet recruiting

  • Research Site

    Port Charlotte, Florida · Not yet recruiting

  • Research Site

    Riverview, Florida · Recruiting

  • Research Site

    Weston, Florida · Not yet recruiting

  • Research Site

    Brunswick, Georgia · Not yet recruiting

  • Research Site

    East Point, Georgia · Not yet recruiting

  • Research Site

    Macon, Georgia · Not yet recruiting

  • Research Site

    Savannah, Georgia · Recruiting

  • Research Site

    Oak Brook, Illinois · Not yet recruiting

  • Research Site

    Rockford, Illinois · Not yet recruiting

  • Research Site

    Iowa City, Iowa · Not yet recruiting

  • Research Site

    Wichita, Kansas · Not yet recruiting

  • Research Site

    Louisville, Kentucky · Recruiting

  • Research Site

    Ann Arbor, Michigan · Not yet recruiting

  • Research Site

    Saint Joseph, Michigan · Not yet recruiting

  • Research Site

    Mankato, Minnesota · Not yet recruiting

Showing 40 of 478 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.